Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nab-paclitaxel (Abraxane) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC): An International, Open-label, Multi-center, Phase 2 Study (LAPACT).

NCT02301143 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT02301143
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02301143 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nab-paclitaxel (Abraxane) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC): An International, Open-label, Multi-center, Phase 2 Study (LAPACT).
Lead sponsor
Celgene
Phase
Phase 2
Overall status
Completed
Start date
April 21, 2015
Completion date
April 26, 2018
Enrollment
107 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic neoplasms